(Q26749511)

22 June 2019

19 September 2019

13 September 2020

3 November 2020

describes a project that uses

7 February 2024

copyright status

copyrighted

0 references

crowdsourcing

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/s12967-016-0838-4

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/s12967-016-0838-4

cites work

The price of innovation: new estimates of drug development costs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847363

How to improve R&D productivity: the pharmaceutical industry's grand challenge

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847363

Believe it or not: how much can we rely on published data on potential drug targets?

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847363

How were new medicines discovered?

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847363

Can the pharmaceutical industry reduce attrition rates?

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847363

A decade of innovation in pharmaceutical R&D: the Chorus model.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847363

Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847363

Clinical development success rates for investigational drugs

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847363

Four disruptive strategies for removing drug discovery bottlenecks

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847363

Diagnosing the decline in pharmaceutical R&D efficiency

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847363

The productivity crisis in pharmaceutical R&D.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847363

US academic drug discovery

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847363

Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847363

Grants4Targets - an innovative approach to translate ideas from basic research into novel drugs

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847363

Can open-source drug R&D repower pharmaceutical innovation?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847363

Trends in risks associated with new drug development: success rates for investigational drugs

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847363

Drug discovery: new models for industry-academic partnerships

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847363

Target-based drug discovery: is something wrong?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847363

Key factors in the rising cost of new drug discovery and development

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847363

Cost of innovation in the pharmaceutical industry

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847363

28 September 2017

2014 FDA drug approvals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847363

GlaxoSmithKline opens the door on clinical data sharing

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847363

Lessons from 60 years of pharmaceutical innovation

31 May 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12967-016-0838-4

21 January 2018

2011 FDA drug approvals

1 reference

https://api.crossref.org/works/10.1186%2FS12967-016-0838-4

21 January 2018

2012 FDA drug approvals

1 reference

https://api.crossref.org/works/10.1186%2FS12967-016-0838-4

21 January 2018

2013 FDA drug approvals

1 reference

https://api.crossref.org/works/10.1186%2FS12967-016-0838-4

Trial watch: phase II and phase III attrition rates 2011-2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12967-016-0838-4

Mergers and innovation in the pharmaceutical industry

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12967-016-0838-4

Models for open innovation in the pharmaceutical industry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12967-016-0838-4

Outsourcing lead optimization: the eye of the storm

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12967-016-0838-4

Grants4Targets: an open innovation initiative to foster drug discovery collaborations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12967-016-0838-4

Novelty in the target landscape of the pharmaceutical industry

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12967-016-0838-4

Rebuilding the R&D engine in big pharma

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847363

Risks in new drug development: approval success rates for investigational drugs

28 November 2018

1 reference

12 December 2020

Pharma embraces open source models

1 reference

12 December 2020

The case for entrepreneurship in R&D in the pharmaceutical industry

1 reference

12 December 2020

Pfizer reaches out to academia--again

1 reference

12 December 2020

2010 FDA drug approvals

1 reference

12 December 2020

Biotechs follow big pharma lead back into academia

1 reference

12 December 2020

The impact of mergers on pharmaceutical R&D

1 reference

12 December 2020

Outlook for the next 5 years in drug innovation

1 reference

12 December 2020

The Impact of Collaborative and Risk-Sharing Innovation Approaches on Clinical and Regulatory Cycle Times

1 reference

12 December 2020

10.1186/S12967-016-0838-4

Identifiers

DOI

1 reference

Dimensions Publication ID

2062949

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/s12967-016-0838-4

2062949

1 reference

1 reference

1 reference